rNAPc2

DRUG2 trials

Sponsors

ARCA Biopharma, Inc.

Conditions

Coronary DiseaseCovid19

Phase 2

Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32

CompletedNCT00116012

ARCA Biopharma, Inc.Coronary Disease

Start: 2005-06-30Target: 300Updated: 2006-11-29

Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19

CompletedNCT04655586

ARCA Biopharma, Inc.Covid19

Start: 2020-12-10End: 2022-03-07Updated: 2023-02-21

Related Papers

Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial

Arteriosclerosis Thrombosis and Vascular Biology2023-06-2911 citations

Abstract 113: Novel Tissue Factor Inhibition For Thromboprophylaxis In COVID-19: Primary Results Of The ASPEN-COVID-19 Phase 2b Randomized Trial

Arteriosclerosis Thrombosis and Vascular Biology2022-05-01

Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial.

2022-01-029 citations

Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial.

2007-06-1151 citations